Table 4.
Recommended antimicrobial therapy for specific pathogens
| Organism | Preferred antimicrobials | Alternative antimicrobials |
|---|---|---|
| S pneumoniae (MIC <2 μg/mL) | Pencillin G; amoxicillin | Macrolide;* telithromycin cephalosporins (oral-cefpodoxime; cefdinir; cefprozil; cefuroxime, cefditoren; parenteral-cefuroxime, ceftriaxone, cefotaxime); clindamycin; doxycyline; fluoroquinolone† |
| S pneumoniae (MIC ≥2 μg/mL) | Agents based on susceptibility tests, including cefotaxime, ceftriaxone, fluoroquinolone† telithromycin (orally, for mild infections) | Vancomycin; linezolid; (high dose amoxicillin, 3 g/day, should be effective for strains with MIC 2–4 μg/mL) |
| H influenzae | Non-β lactamase producing: amoxicillin β lactamase producing: second or third generation cephalosporin; amoxicillin/clavulanate | Fluoroquinolone; doxycycline; azithromycin; clarithromycin‡ |
| M pneumoniae/C pneumoniae | Macrolide; a tetracycline | Fluoroquinolone† |
| Legionella spp | Fluoroquinolone;§ azithromycin, clarithromycin | Doxycycline |
| C psittaci | A tetracycline | Macrolide |
| Cox burnetii | A tetracycline | Macrolide |
| Enterobacteriaceae | Third generation cephalosporin; carbapenem | β lactam β lactamase inhibitor¶; fluoroquinolone |
| P aeruginosa | Aminoglycoside plus antipseudomonal β lactam|| | Aminoglycoside plus ciprofloxacin; ciprofloxacin or high dose levofloxacin** plus antipseudomonal lactam |
| Methicillin susceptible S aureus | Anti-staph penicillin†† | Cefazolin; clindamycin |
| Methicillin resistant S aureus | Vancomycin | Teicoplanin; linezolid |
| Anaerobe (aspiration) Influenza | β lactam β lactamase inhibitor¶; clindamycin Amantadine or rimantadine (influenza A); oseltamivir or zanamivir (influenza A or B) | Carbapenem‡‡ |
Based on recommendations from IDSA and British Thoracic Society guidelines (choices should be modified based on susceptibility tests results and advice from local specialists. Refer to local references for appropriate doses)
Strains with reduced susceptibility to penicillin should have verified in-vitro susceptibility.
Levofloxacin, gatifloxacin, moxifloxacin (not a first-line choice for penicillin susceptible strains); ciprofloxacin is appropriate for Legionella, and most gram-negative bacilli (including H influenza).
Azithromycin more active in vitro than clarithromycin for H influenza.
Author's preference.
ticarcillin/clavulanate; piperacillin/tazobactam for gram-negative bacilli; ampicillin/sulbactam or amoxicillin/clavulanate appropriate for oral anaerobes. ||ticarcillin, piperacillin, ceftazidime; cefepime, aztreonam, imipenem, meropenem.
750 mg one daily.
nafcillin, oxacillin flucloxacillin.
imipenem/cilastatin; meropenem; ertapenem.